HLB bioStep Co.Ltd.

As of June 30, 2026, HLB bioStep Co.Ltd. carries a market capitalization of 49.23B, placing it among publicly traded companies globally. Its enterprise value stands at 49.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HLB bioStep Co.Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, HLB bioStep Co.Ltd. has 17.21M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.53, and the price-to-book ratio stands at 0.53.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 49.78B versus a market cap of 49.23B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HLB bioStep Co.Ltd. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.10, indicating elevated leverage, while an interest coverage ratio of -0.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, HLB bioStep Co.Ltd. posted a negative return on equity (ROE) of -18.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.14, reflecting losses generated across the asset base. The company generates approximately 467.75M in revenue per employee across its workforce of 154.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 10.16 indicates how many times HLB bioStep Co.Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, HLB bioStep Co.Ltd. recorded 2.59B in income tax expense. The company reported a pretax loss of -16.81B and -18.43B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, HLB bioStep Co.Ltd.'s stock has declined approximately 1.14% over the past 52 weeks. The 50-day moving average sits at 3,303.60, while the 200-day moving average is 4,769.76.

Over the twelve months ended June 30, 2026, HLB bioStep Co.Ltd. generated 72.15B in revenue and converted that into -18.43B in net income, yielding earnings per share of -501.28. EBITDA reached -1.46B, while operating income came in at -6.28B.

As of June 30, 2026, HLB bioStep Co.Ltd. holds 35.01B in cash and equivalents against 31.02B in total debt, resulting in a net debt position of -3.21B. Total book value stands at 92.05B, with working capital of 11.72B providing operational flexibility.

HLB bioStep Co.Ltd. produced 966.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.55B in capital expenditures, free cash flow totaled -2.58B - equivalent to -66.77 per share.

Over the twelve months ended June 30, 2026, HLB bioStep Co.Ltd. posted a gross margin of 73.87, reflecting its pricing power and cost economics. The operating margin of -8.70 and net profit margin of -25.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.24, meaning HLB bioStep Co.Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HLB bioStep Co.Ltd.'s most recent stock split took place on May 18, 2026 with a 5:1 split ratio.

As of June 30, 2026, HLB bioStep Co.Ltd. has an Altman Z-Score of 1.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.